Eli Lilly and Co.

Description goes here

ARTICLES

Lilly adds $375M to Zymeworks partnership

Eli Lilly and Co. and Zymeworks said Wednesday that they are expanding a cancer drug development partnership.
Read More

Lilly third-quarter earnings fall below Wall Street's expectations

The Indianapolis drugmaker's profit tumbled 58 percent as cheaper generic medicines took sales from blockbusters Cymbalta and Evista.
Read More

Eli Lilly to sell Puerto Rico manufacturing facility

The Indianapolis company said it is closing its Guayama facility because the patents on some of the drugs made there have expired.
Read More

Lilly partner ordered to pay more than $2M to ex-Actos user

Takeda Pharmaceutical Co. was ordered by a jury to pay more than $2 million to a woman who claimed the company’s Actos diabetes medicine caused her bladder cancer, in the latest of thousands of lawsuits involving the drug to go to trial.
Read More

Lilly partner accused of putting Actos profit ahead of safety

Executives knew by 2004 that studies found links between Actos and cancer, and didn’t issue a warning until seven years later to protect billions of dollars in sales of the drug, attorney Michael Miller told a state-court jury in Philadelphia on Thursday.
Read More

European regulators OK Lilly's $5.4B Novartis deal

The European Union's antitrust authority has approved the $5.4 billion sale of Novartis' animal health division to Indianapolis-based pharmaceutical firm Eli Lilly and Co.
Read More

Lilly to end development of lupus drug after trial failure

Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
Read More

Testosterone drugs need study on heart risks, FDA panel says

Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.
Read More

FDA set to review testosterone-boosting drug usage

Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
Read More

Lilly to pay AstraZeneca up to $500M in Alzheimer’s push

The two companies will work together to develop AZD3293, which belongs to a novel class of drugs called BACE inhibitors that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Read More